Skip to main content

Organicell Regenerative Medicine Stock Forecast, Price & News

-0.02 (-8.30 %)
(As of 05/14/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume4.36 million shs
Average Volume4.80 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive BPSR News and Ratings via Email

Sign-up to receive the latest news and ratings for Organicell Regenerative Medicine and its competitors with MarketBeat's FREE daily newsletter.

About Organicell Regenerative Medicine

Organicell Regenerative Medicine, Inc., a clinical-stage biopharmaceutical company, focuses on the development of biological therapeutics for the treatment of degenerative diseases. Its leading product candidate is Zofin, an acellular, biologic therapeutic derived from perinatal sources and is manufactured to retain naturally occurring microRNAs without the addition or combination of any other substance or diluent, which is in Phase I/II clinical trial to treat COVID-19. Zofin contains approximately 300 growth factors, cytokines, chemokines, and 102 unique microRNAs, as well as other exosomes/nanoparticles derived from perinatal tissues. It also provides independent education, advertising, and marketing services to medical and other healthcare, anti-aging, and regenerative service providers. Organicell Regenerative Medicine, Inc. has a research and development agreement with the Centers for Disease Control and Prevention to determine the anti-inflammatory and anti-infective effectiveness of Zofin in experimental models of influenza infection; and an agreement with Oklahoma State University to evaluate Zofin for the treatment of respiratory diseases caused by virus infections of pandemic potential. The company was formerly known as Biotech Products Services and Research, Inc. and changed its name to Organicell Regenerative Medicine, Inc. in June 2018. Organicell Regenerative Medicine, Inc. was founded in 2011 and is headquartered in Miami, Florida.


See More Headlines

Industry, Sector and Symbol

Industry Biotechnology
Current SymbolOTCMKTS:BPSR
Phone(888) 963-7881
Year FoundedN/A

Sales & Book Value

Annual SalesN/A





Next Earnings DateN/A
OptionableNot Optionable


Overall MarketRank

0.54 out of 5 stars

Medical Sector

1504th out of 2,044 stocks

Biotechnology Industry

84th out of 158 stocks

Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Organicell Regenerative Medicine (OTCMKTS:BPSR) Frequently Asked Questions

What stocks does MarketBeat like better than Organicell Regenerative Medicine?

Wall Street analysts have given Organicell Regenerative Medicine a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Organicell Regenerative Medicine wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Organicell Regenerative Medicine?

Organicell Regenerative Medicine saw a drop in short interest during the month of April. As of April 15th, there was short interest totaling 9,500 shares, a drop of 72.9% from the March 31st total of 35,100 shares. Based on an average daily trading volume, of 817,000 shares, the days-to-cover ratio is currently 0.0 days.
View Organicell Regenerative Medicine's Short Interest

How has Organicell Regenerative Medicine's stock been impacted by Coronavirus (COVID-19)?

Organicell Regenerative Medicine's stock was trading at $0.0280 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, BPSR stock has increased by 689.3% and is now trading at $0.2210.
View which stocks have been most impacted by COVID-19

Who are Organicell Regenerative Medicine's key executives?

Organicell Regenerative Medicine's management team includes the following people:
  • Mr. Albert Mitrani, Co-Founder, CEO, COO, Pres, Sec., Treasurer & Director (Age 66, Pay $488.14k)
  • Dr. Maria Ines Mitrani, Co-Founder, VP, Chief Science Officer & Director (Age 41, Pay $337.5k)
  • Mr. Ian T. Bothwell, CFO & Director (Age 61, Pay $337.5k)
  • Dr. George C. Shapiro FACC, M.D., Chief Medical Officer & Director (Age 59, Pay $54.83k)

Who are some of Organicell Regenerative Medicine's key competitors?

What other stocks do shareholders of Organicell Regenerative Medicine own?

What is Organicell Regenerative Medicine's stock symbol?

Organicell Regenerative Medicine trades on the OTCMKTS under the ticker symbol "BPSR."

How do I buy shares of Organicell Regenerative Medicine?

Shares of BPSR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Organicell Regenerative Medicine's stock price today?

One share of BPSR stock can currently be purchased for approximately $0.22.

How many employees does Organicell Regenerative Medicine have?

Organicell Regenerative Medicine employs 18 workers across the globe.

What is Organicell Regenerative Medicine's official website?

The official website for Organicell Regenerative Medicine is

Where are Organicell Regenerative Medicine's headquarters?

Organicell Regenerative Medicine is headquartered at 4045 Sheridan Avenue,Suite 239, MIAMI, FL 33140, United States.

How can I contact Organicell Regenerative Medicine?

Organicell Regenerative Medicine's mailing address is 4045 Sheridan Avenue,Suite 239, MIAMI, FL 33140, United States. The company can be reached via phone at (888) 963-7881.

This page was last updated on 5/15/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.